In late August, centuries-old pharmaceutical company Pfizer did something new: embraced the blockchain.
In a request to join VitaDAO, a blockchain-based biotech collective that requires cryptocurrency buy-in, Pfizer expressed interest in VitaDAO’s pursuit of drugs that could extend one’s lifespan and wanted to work with the collective as a stakeholder (Pfizer declined to comment for this article). READ MORE